RICTOR and small cell lung carcinoma: RICTOR amplification has been identified as the most common targetable genetic alteration in SCLC cases [27, 31, 33], and its possible role in metastasis formation [111, 127] underlines the need for biomarker-driven clinical studies with mTORC1/2 or even selective mTORC2 inhibitors in case the latter will also be available for clinical use.